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Abstract
Purpose—To investigate associations between computed tomography (CT) features of clear-cell
renal cell carcinoma (ccRCC) and mutations in VHL, PBRM1, SETD2, KDM5C or BAP1 genes.
Materials and Methods—The institutional review board approved this retrospective,
hypotheses-generating study of 233 patients with ccRCC and waived the informed consent
requirement. The study was HIPAA compliant. Three radiologists independently reviewed pre-
treatment CT images of all ccRCC without knowledge of their genomic profile. One radiologist
measured largest diameter and enhancement parameters of each ccRCC. Associations between CT
features and mutations in VHL, PBRM1, SETD2, KDM5C and BAP1 genes were tested using
Fisher’s exact tests. Associations between mutations and size/enhancement were assessed using
independent t-tests. Interreader agreements were calculated using Fleiss’ Kappa.
Results—Mutation frequencies among ccRCC were: VHL, 53.2% (124/233); PBRM1, 28.8%
(67/233); SETD2, 7.3% (17/233); KDM5C, 6.9% (16/233); BAP1, 6% (14/233). Mutations of VHL
were significantly associated with well-defined tumor margins (p=0.013), nodular tumor
enhancement (p=0.021) and gross appearance of intratumoral vascularity (p=0.018). Mutations of
KDM5C and BAP1 were significantly associated with evidence of renal vein invasion (p=0.022
and 0.046, respectively). The genotype of solid ccRCC differed significantly from the one of
multicystic ccRCC. While mutations of SETD2, KDM5C and BAP1 were absent in multicystic
ccRCC, mutations of VHL (p=0.016) and PBRM1 (p=0.017) were significantly more common
among solid ccRCC. Interreader agreements for CT feature assessments ranged from substantial to
excellent (κ=0.791–0.912).
Conclusion—This preliminary Radiogenomics analysis of ccRCC revealed associations
between CT features and underlying mutations which warrant further investigation and validation.
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INTRODUCTION
The genomic landscape of clear-cell renal cell carcinoma (ccRCC) was long thought to be
dominated by the mutation of the von Hippel-Lindau tumor suppressor, E3 ubiquitin protein
ligase (VHL) gene located on the short arm of chromosome 3 (3p25). Loss of VHL function
has up-regulating effects on hypoxia inducible factors, which play a key role in triggering
neo-angiogenic activity of ccRCC. Recent advances in whole genome sequencing of ccRCC
have led to the identification of the following histone modifying and chromatin remodeling
gene mutations: polybromo 1 (PBRM1), SET domain containing 2 (SETD2), lysine (K)-
specific demethylase 5C (KDM5C), and BRCA1 associated protein-1 (ubiquitin carboxy-
terminal hydrolase) (BAP1) (1–5). While KDM5C is part of the short arm of chromosome X
(Xp11), PBRM1, SETD2, and BAP1 are located on the short arm of chromosome 3 (3p21) -
in close proximity to VHL. Mutations of VHL, PBRM1, BAP1, SETD2 and KDM5C were
recently found to be associated with advanced stage, advanced grade, and possibly worse
cancer specific survival (6, 7).
Diagnostic imaging of RCC is primarily based on tumor detection, cytological subtype
characterization, definition of location and extent, and treatment response assessment.
Computed tomography (CT), by its potential to fulfill these tasks (8), continues to contribute
to clinical decision-making and serves as the primary basis for staging and treatment
response assessment (9, 10). However, as the diagnostic standard of reference is rapidly
expanding to the genomic level, the role of CT in ccRCC needs to be refined. In the near
future, demonstrating the presence, location, and extent of ccRCC may not be sufficient
when challenged by critical questions of which molecular drug to apply, which patients to
select for active surveillance, or whether early response to treatment is evident or not (11).
For an integrated diagnostic approach between Radiology and Genomics, the term
“Radiogenomics” has been established (12, 13).
The critical first step of testing the robustness of Radiogenomics embodies the establishment
of predictable and systematic associations between imaging features and underlying
molecular and genomic alterations of ccRCC. A recent study investigated a similar approach
in lung cancer and discovered significant associations between imaging features and
mutations (14). Another recent study investigated magnetic resonance imaging (MRI)
features of breast cancer in correlation to underlying mutations and identified 21 imaging
traits that were globally correlated with multiple, recently discovered breast cancer
mutations (15). In another study, cerebral edema and cellular invasion caused by
glioblastoma and illustrated by MRI had been linked to a specific up-regulated gene (16). In
ccRCC, one study had been published on the investigation of associations between CT
features of 58 ccRCC and the underlying karyotype (17). However, so far no study has
investigated associations between CT features of ccRCC and the underlying genotype.
The objective of this hypotheses-generating Radiogenomics study was to investigate
associations between CT features of ccRCC and mutations of the genes VHL, PBRM1,
SETD2, KDM5C, and BAP1.
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MATERIALS AND METHODS
Patients
The institutional review board approved this retrospective study and waived the requirement
for informed consent regarding the acquisition of CT data. However, all patients provided
written informed consent for their ccRCC tissue to be used for genome sequencing. The
study was compliant with the health insurance portability and accountability act (HIPAA).
Patients were included in this study upon fulfillment of the following criteria:
I. Histopathological diagnosis of ccRCC and genome sequencing including
information on mutations of the chromatin modifying genes PBRM1, SETD2,
BAP1, KDM5C and VHL, which have been considered the most frequent mutations
in ccRCC (6).
II. Availability of a pre-treatment, contrast-enhanced CT study through our
institution’s picture archiving and communications system (PACS), either in digital
imaging and communications in medicine (DICOM) format or as scanned film
prints.
Information regarding the mutations of PBRM1, SETD2, BAP1, KDM5C and VHL were
available for 289 ccRCC from two distinct cohorts (i.e. institutional cohort and TCGA
cohort). We were able to retrieve pre-treatment contrast-enhanced CT studies for 80.6%
(233/289) of patients. 6.4% (15/233) were scanned film prints and 93.6% (218/233) were
available in DICOM format. Of the CT studies performed at our institution, 79.6%
(121/152) had been acquired using our institutional, tri-phasic kidney protocol consisting of
a non-contrast-enhanced data acquisition and contrast-enhanced acquisitions during the
nephrographic and excretory phases. Demographic and tumor characteristics of all 233
patients are summarized in Table 1.
Select gene sequencing and identification of mutations
Mutation information for the 233 ccRCC, for whom we were able to retrieve contrast-
enhanced CT studies, was retrieved from The Cancer Genome Atlas (TCGA) web portal for
34.3% (80/233) of cases, and from a distinct cohort sequenced at our institution for 65.7%
(153/233) of ccRCC. Mutation analyses of the entire coding regions of VHL, PBRM1,
SETD2, BAP1, and KDM5C for 65.7% (153/233) of ccRCC were performed at our
institution using polymerase chain reaction amplification and bidirectional Sanger
sequencing, as previously described by Hakimi et al. (6). For the remaining 80 cases,
mutation data was acquired from our institution’s contribution to the TCGA ccRCC project.
Non-silent, coding mutations were considered for both cohorts, with truncating mutations
defined as nonsense, frameshift, or essential splice site (within first 2 base-pairs of coding
region).
CT image acquisition and analysis
65.2% (152/233) of pre-treatment, contrast-enhanced CT studies had been performed at our
institution and 34.8% (81/233) at outside institutions. Through our PACS, 81.5% (66/81) of
outside CT studies were available as complete DICOM data sets and 18.5% (15/81) as
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scanned film prints. Regarding the CT studies from our institution, 79.6% (121/152) had
been performed using a dedicated renal mass protocol consisting of a non-enhanced data
acquisition and data acquisitions during the nephrographic (delay, 90 sec) and excretory
(delay, 3 minutes) phase after the application of 150 mL of iodinated contrast agent at a
constant flow rate of 3.5 mL/sec. At identical scan and contrast material parameters, 21.4%
(31/152) of CT studies from our institution had been acquired during the nephrographic
phase only.
For the qualitative ccRCC feature analysis, we used all available contrast-enhanced CT
studies (n=233). While we performed tumor size measurements only on contrast-enhanced
CT images available in DICOM format (n=218), tumor enhancement measurements were
performed exclusively on CT studies from our institution that had been acquired using the
dedicated renal mass protocol (n=121) in order to avoid inhomogeneity in scan parameters.
Three radiologists with different degrees of experience in interpreting genitourinary CT
images independently performed all qualitative image analyses. One radiologist was an
assistant attending with 4 years of experience (__), the other two radiologists were research
fellows with 5 years (__) and 4 years (__) of experience. All three radiologists analyzed all
CT studies without access to genomic data. All three radiologists were aware that each
patient had at least one ccRCC. After each Radiologist had finished the analysis, a
consensus was established for each qualitative CT feature as follows: If there was
disagreement between the readers, the matching results of two readers were chosen for
further analysis. This consensus was performed for all features and in all patients.
The following eight qualitative features of ccRCC were analyzed by all readers (Figure 1):
(I) necrosis, defined as either the presence or absence of areas within the tumor that did not
demonstrate contrast enhancement during the nephrographic and delayed phase; (II)
presence or absence of intratumoral calcifications; (III) definition of tumor margin as either
ill- or well-defined; (IV) definition of tumor architecture as either solid or multicystic; (V)
absence or presence of collecting system invasion, defined as evidence of a filling defect on
excretory phase images; (VI) absence or presence of renal vein invasion, defined as
evidence of a filling defect within the renal vein or its branches on nephrographic-phase
images; (VII) gross evidence of intratumoral vascularity on nephrographic-phase CT
images; (VIII) definition of tumor enhancement pattern on nephrographic-phase images as
either homogeneous or nodular.
In addition to the qualitative feature analysis, one radiologist measured the greatest diameter
of each ccRCC on transverse nephrographic-phase images and the enhancement within the
most enhancing component of each ccRCC and within the renal cortex on transverse images
during the non-enhanced, nephrographic and excretory, contrast-enhanced phases, and noted
the average enhancement from region of interest analysis (ROI) in Hounsfield units (HU).
This enhancement analysis was performed only for the CT studies performed at our
institution using a dedicated renal mass protocol. Nephrographic-phase enhancement was
calculated as the percentage increase between non-enhanced and nephrographic-phase,
contrast-enhanced HU measurements for the renal cortex and the ccRCC. The percentage
difference in enhancement between the ccRCC and the renal cortex were calculated. The
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percentage difference in enhancement of ccRCC between the nephrographic and excretory,
contrast enhanced phases was calculated.
Statistical analysis
To assess interreader agreements regarding qualitative feature analyses between the three
readers, Fleiss’ Kappa was calculated separately for each feature and interpreted as follows:
< 0.20, poor agreement; 0.20–0.40, fair agreement; 0.40–0.60, moderate agreement; 0.60–
0.80, substantial agreement; and 0.80–1.00, excellent agreement. Fisher’s exact tests were
performed to assess for significant differences in distribution of each qualitative CT feature
among each mutation (i.e. VHL, PBRM1, BAP1, SETD2 and KDM5C). To assess for
significant differences in quantitative features (enhancement and size parameters) among
each mutation, independent t-tests were performed. Relative risk (including 95% confidence
intervals) for the evidence of each CT imaging feature was calculated for each mutation.
Two-sided P values of less than .05 were considered to indicate statistically significant
differences. All statistical analyses were performed by using commercially available
statistics software (SPSS, version 19; IBM, Armonk, NY).
RESULTS
Demographic and tumor characteristics of all 233 patients are summarized in Table 1.
Frequency of mutations
Mutation of VHL was identified in 53.2% (124/233) of ccRCC, followed by mutations of
PBRM1 (28.8% [67/233]), SETD2 (7.3% ([17/233]), KDM5C (6.9% [16/233]), and BAP1
(6% [14/233]) (Figure 2).
Qualitative CT Feature Analysis
Frequencies of all CT features per mutation, as illustrated in Figures 2 and 3, are
summarized in Table 2. Interreader agreements for the assessment of qualitative tumor
features on CT images ranged from substantial to excellent (κ=0.791–0.912).
Radiogenomic Associations
Mutations of the VHL gene were significantly associated with the following phenotypic
characteristics of clear-cell renal cell carcinoma (ccRCC) on contrast-enhanced computed
tomography (CT): well-defined tumor margins (p=0.013), nodular tumor enhancement
(p=0.021) and gross appearance of intratumoral vascularity (p=0.018).
Mutations of the KDM5C and BAP1 genes were significantly associated with evidence of
renal vein invasion on contrast-enhanced CT of ccRCC (p=0.022 and 0.046, respectively)
The genotype of solid ccRCC differed significantly from the one of multicystic ccRCC.
While mutations of SETD2, KDM5C and BAP1 were completely absent in multicystic
ccRCC, mutations of VHL (p=0.016) and PBRM1 (p=0.017) were significantly more
common among solid ccRCC. SETD2 mutations were not significantly associated with any
qualitative CT feature investigated. Radiogenomic associations are summarized in Table 2
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and illustrated in Supplementary Figure 3. Results from all risk analyses are presented in
Table 3.
Quantitative Feature Analysis
In the presence of a mutation of KDM5C, ccRCC demonstrated significantly lower contrast
enhancement during the nephrographic phase when compared to the renal cortex (p=0.030)
(Table 4). No other associations between enhancement parameters and mutations were
discovered. Tumor size, as measured on contrast-enhanced CT images, was not associated
with any of the investigated mutations (Table 4).
DISCUSSION
The investigation of individual associations between diagnostic imaging features and
mutations is considered the critical first step of Radiogenomics of ccRCC (11). While the
genomic landscape of ccRCC has long been dominated by the loss of VHL function, recent
advances in cancer genome sequencing of ccRCC have led to the identification of
additional, prognostically significant mutations in ccRCC. This is the first hypotheses-
generating study of potential associations between individual CT features of ccRCC and
mutations of the genes VHL, PBRM1, BAP1, SETD2, and KDM5C. This study yielded the
following results:
Well-defined tumor margins were significantly more common among ccRCC with loss of
VHL function. Well-defined tumor margins are considered an indicator of less infiltrative
behavior and thus lower aggressiveness of ccRCC when compared to ccRCC with ill-
defined margins (18). This observation therefore warrants further investigation and
validation, because well-defined margins of ccRCC on CT imaging may indicate a loss of
VHL function.
Nodular, heterogeneous enhancement of ccRCC and evidence of intratumoral vasculature on
contrast-enhanced CT images were significantly more common among ccRCC with
underlying VHL mutations. This may be explained by the fact, that a loss of VHL function is
associated with an up-regulation of hypoxia inducible factors and an overexpression of
angiogenic factors such as vascular endothelial growth factor. This angiogenic activity may
thus be reflected on contrast-enhanced CT images by evidence of nodular, heterogeneous
enhancement and visibility of intratumoral blood vessels. This finding should be further
investigated and validated using standardized CT imaging in larger cohorts.
Another finding of this study was that ccRCC with mutations of BAP1 and KDM5C were
associated with an increased evidence of renal vein invasion. This observation supports
previously published reports demonstrating that mutations of PBRM1, SETD2, BAP1, and/or
KDM5C in ccRCC were associated with advanced stage, grade, and tumor invasiveness (6,
7).
Solid ccRCC were associated with a substantially different genotype when compared to
multicystic ccRCC. While mutations of VHL and PBRM1 were more common among solid
ccRCC, mutations of SETD2, KDM5C and BAP1 were absent in multicystic ccRCC. This
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finding supports a recently published study that multicystic ccRCC in fact represent less
aggressive ccRCC of relatively low malignant potential (19). However, due to the small
sample size of multicystic ccRCC in our study (n=19), this observation warrants further
validation in a larger cohort.
This study had the following limitations: First, it is a discovery-phase study without
validation of the findings. However, we discovered associations between mutations and CT
imaging features of ccRCC, which may assist in the selection of features for future studies.
We did not correct for multiple hypothesis testing, which may be regarded as an additional
limitation of this study. However, this study was primarily executed as a preliminary,
discovery-phase analysis of Radiogenomic associations in ccRCC. Another limitation of this
study was that the CT studies had been performed at different institutions using different CT
scanners. However, this was a retrospective analysis in which we aimed to keep the sample
size as lage as possible. In addition, we only used CT studies from our institution, which had
been performed using a dedicated renal mass protocol, for enhancement analyses. In
addition, the amount of contrast material applied to each patient was not weight corrected,
therefore CT features associated with enhancement could be affected due to the different
weight based doses that were administered. Regarding the genomic findings, our data was
recorded as mutations or no mutations. This may be considered a limitation, because genes
may loose their function through copy number errors or epigenetic defects as well. However,
this is thought to be rather limited to VHL, with a methylation rate of 5–10%. Data from the
TCGA project suggest that none of the other genes investigated in this study were
methylated or homozygously deleted. Furthermore, ccRCC frequently exhibit varying
amounts of intratumoral heterogeneity, which may substantially alter the genomic landscape
within ccRCC (20). That is, ccRCC frequently consist of several genetically different
components that may be illustrated as a whole by CT, but represent a challenge for tissue
sampling for whole genome sequencing. Therefore, imaging may be useful to guide tissue
sampling in the future in order to ensure that the most aggressive or prognostically relevant
tumor component is being chosen for the acquisition of tissue for genomic sequencing.
In summary, this preliminary Radiogenomics analysis of ccRCC revealed associations
between CT features and underlying mutations and therefore warrants further investigation
and validation. Moreover, future studies are necessary to combine individual CT features
into CT imaging phenotypes of ccRCC and correlate them to underlying genomic profiles
rather than individual gene mutations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Advances in knowledge
1. Mutations of the VHL gene were significantly associated with the following
phenotypic characteristics of clear-cell renal cell carcinoma (ccRCC) on
contrast-enhanced computed tomography (CT): well-defined tumor margins
(p=0.013), nodular tumor enhancement (p=0.021) and gross appearance of
intratumoral vascularity (p=0.018).
2. Mutations of the KDM5C and BAP1 genes were significantly associated with
evidence of renal vein invasion on contrast-enhanced CT of ccRCC (p=0.022
and 0.046, respectively)
3. The genotype of solid ccRCC differed significantly from the one of multicystic
ccRCC. While mutations of SETD2, KDM5C and BAP1 were completely absent
in multicystic ccRCC, mutations of VHL (p=0.016) and PBRM1 (p=0.017) were
significantly more common among solid ccRCC.
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Figure 1.
Illustration of CT features of clear-cell renal cell carcinoma (ccRCC) investigated in this study: (A) necrosis; (B) renal vein
invasion; (C) ill-defined margin; (D) nodular enhancement; (E) calcifications; (F) multicystic architecture; (G) collecting system
invasion; (H) gross appearance of intratumoral vasculature.
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Figure 2.
Subject-based color map illustrating mutations and CT features.
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Table 1
Demographics and mutations
Patient demographics and mutational information.
Gender
Female 27.5% (64/233)
Male 72.5% (169/233)
Clinical Presentation
Incidental 75.5% (176/233)
Localized 19.3% (45/233)
Systemic 4.3% (10/233)
Unknown 0.9% (2/233)
Type of Surgery
Radical 41.2% (96/233)
Partial 58.8% (137/233)
Side
Left 49.4% (115/233)
Right 50.6% (118/233)
Localized clear-cell RCC
no 46.4% (108/233)
yes 53.6% (125/233)
Fuhrman Grade
1 0.4% (1/233)
2 41.6% (97/233)
3 48.5% (113/233)
4 9.4% (22/233)
Mutations
VHL 53.2% (124/233)
PBRM1 28.8% (67/233)
SETD2 7.3% (17/233)
BAP1 6% (14/233)
KDM5C 6.9% (16/233)
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